Chief Financial Officer (11) · Insight Molecular Diagnostics Inc. (IMDX)

Mitchell Levine

A named executive officer of Insight Molecular Diagnostics in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,561,915

Salary $356,895Stock awards $0Bonus $110,638

FY2020: $1,058,460

3rd of 3 named executive officers at Insight Molecular Diagnostics by FY2021 total.

3 named officers on file for Insight Molecular Diagnostics, FY2021

Mitchell Levine’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Insight Molecular Diagnostics’s whole pay program stands against its peers

  • Insight Molecular Diagnostics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 8, 2022 (DEF 14A).

Free

Get Mitchell Levine’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mitchell Levine compensation by year

Insight Molecular Diagnostics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Insight Molecular Diagnostics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021
Salary$41,885$314,008$343,063$361,999$356,895
Bonus$8,684$200,000$131,670$131,670$110,638
Stock awards$0$0$70,400$44,800$0
Option awards$578,991$359,287$600,142$504,431$1,081,200
Non-equity incentive$0$0$0$0$0
Pension and deferred compensation$0$0$0$721$0
All other$0$0$12,662$14,839$13,182
Total$629,560$873,295$1,157,937$1,058,460$1,561,915

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Insight Molecular Diagnostics Inc. DEF 14A filed June 8, 2022, accession 0001493152-22-016178, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Insight Molecular Diagnostics Inc. filed document, accession 0001493152-22-016178. Every figure is read from that document and cited to the page and table it appears in. Filed June 8, 2022.

$630K
$873K
$1.2M
$1.1M
$1.6M
FY17
FY18
FY19
FY20
FY21
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option204,000—$2.63
Option255,000—$5.34
Option5,208—$2.35
Option76,563—$3.52

Per the Outstanding Equity Awards at Fiscal Year-End table in Insight Molecular Diagnostics Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insight Molecular Diagnostics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Ronald AndrewsPresident and Chief Executive Officer$2,921,838
Douglas RossChief Science Officer (12)$1,640,137
Mitchell Levine · this pageChief Financial Officer (11)$1,561,915

The full Insight Molecular Diagnostics compensation record

free company brief

This page is one person within Insight Molecular Diagnostics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Insight Molecular Diagnostics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mitchell Levine's compensation dossier · One-time report. No refunds.